ArticleCancer chemotherapy and pharmacology2026

A phase 1, open-label study evaluating the pharmacokinetics, safety, and tolerability of vepdegestrant in Chinese patients with ER+/HER2- advanced breast cancer.

Binghe Xu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.